TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock Has Consensus Target Price of $10.20

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $10.20.

Several brokerages have recently weighed in on TLSI. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Stifel Nicolaus set a $12.00 price objective on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Guggenheim set a $12.00 target price on TriSalus Life Sciences in a research report on Wednesday, September 23rd. HC Wainwright lifted their target price on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. Finally, Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in TriSalus Life Sciences by 86.3% during the second quarter. State Street Corp now owns 610,963 shares of the company’s stock valued at $2,780,000 after purchasing an additional 282,943 shares in the last quarter. First Light Asset Management LLC boosted its position in shares of TriSalus Life Sciences by 29.3% in the second quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock worth $29,814,000 after purchasing an additional 1,485,664 shares during the period. Corient Private Wealth LP increased its stake in shares of TriSalus Life Sciences by 61.7% in the second quarter. Corient Private Wealth LP now owns 147,152 shares of the company’s stock worth $670,000 after purchasing an additional 56,152 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at $4,550,000. Finally, Bank of America Corp DE bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at $934,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Down 2.8%

TLSI stock opened at $4.13 on Friday. TriSalus Life Sciences has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The business’s 50-day moving average is $4.89 and its two-hundred day moving average is $4.33. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. The company has a market cap of $254.33 million, a price-to-earnings ratio of -3.18 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million. As a group, analysts forecast that TriSalus Life Sciences will post -0.53 earnings per share for the current year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is an oncology-focused life sciences company developing medical technologies and therapies for patients with difficult-to-treat liver and pancreatic tumors. The company’s approach is designed to address the unique biological and physical barriers that can limit the delivery of cancer treatments to solid tumors.

TriSalus’ principal technology is its Pressure-Enabled Drug Delivery (PEDD) platform, which is intended to improve the distribution of therapeutic agents within tumors through regional infusion.